Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study

Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study

Item
http://www.wikidata.org/entity/Q34458029
Progress in systemic therapy of advanced hepatocellular carcinomaManagement of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.Drug development for hepatocellular carcinoma: knowing the past helps to understand the futureEfficacy and safety of the oxaliplatin-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma: A meta-analysis of prospective studiesChemotherapy for hepatocellular carcinoma: The present and the future.Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.Epithelial-mesenchymal transition plays a critical role in drug resistance of hepatocellular carcinoma cells to oxaliplatin.T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC.Prognostic Nomogram for Advanced Hepatocellular Carcinoma Treated with FOLFOX 4A proteomics-based investigation on the anticancer activity of alisertib, an Aurora kinase A inhibitor, in hepatocellular carcinoma Hep3B cells.Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future.Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin.Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells.GP73 level determines chemotherapeutic resistance in human hepatocellular carcinoma cells.Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China
P2860

Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study

Item
http://www.wikidata.org/entity/Q34458029
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of the FOL ...... oup analysis of the EACH study
@ast
Efficacy and safety of the FOL ...... oup analysis of the EACH study
@en
Efficacy and safety of the FOL ...... oup analysis of the EACH study
@nl
type
label
Efficacy and safety of the FOL ...... oup analysis of the EACH study
@ast
Efficacy and safety of the FOL ...... oup analysis of the EACH study
@en
Efficacy and safety of the FOL ...... oup analysis of the EACH study
@nl
prefLabel
Efficacy and safety of the FOL ...... oup analysis of the EACH study
@ast
Efficacy and safety of the FOL ...... oup analysis of the EACH study
@en
Efficacy and safety of the FOL ...... oup analysis of the EACH study
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Efficacy and safety of the FOL ...... oup analysis of the EACH study
@en
P2093
P2860
P304
P31
P356
10.1634/THEONCOLOGIST.2014-0190
P433
P478
P577
P5875
P698
P932